Sirona Biochem to Present at 2nd Annual Marcum MicroCap Conference in New York
13 5월 2013 - 9:55PM
OTC Markets
Sirona Biochem
Corp. (TSX-V:
SBM, OTCQX:
SRBCF, Frankfurt:
ZSB) today announced it will present at the 2nd
Annual Marcum MicroCap Conference at the Grand
Hyatt in New York, NY on May 30, 2013.
Sirona
Biochem’s Chief Executive Officer, Neil Belenkie will be the
company’s presenter. The presentation will be webcast live and a
link to the webcast will be made available and announced at a later
date.
Presentation
details as follows:
Date
and Time: 10:30am-11:00am EDT, May 30, 2013
Venue:
Grand Hyatt, New York, NY, Estate 6 Room
Presenter:
Neil Belenkie, Chief Executive Officer of Sirona Biochem
About Sirona
Biochem Corp.
Sirona
Biochem is a biotechnology company developing diabetes
therapeutics, skin depigmenting and anti-aging agents for cosmetic
use, biological ingredients and cancer vaccine
antigens. The company
utilizes a proprietary chemistry technique to improve
pharmaceutical properties of carbohydrate-based molecules. Sirona
Biochem is the parent company of French-based biotechnology
company, TFChem. For
more information visit www.sironabiochem.com.
About the
Marcum MicroCap Conference
The
Marcum MicroCap Conference is dedicated to introducing investors to
the very best, undiscovered companies under $500 million in market
capitalization.
The Conference is expected to draw more than 1,000 attendees
including senior personnel from almost 100 presenting public
companies. This invitation-only event attracts institutional
investors including top fund managers and qualified high net worth
investors, who focus on small cap equities.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
For more
information regarding this press release, contact:
Christopher
Hopton
Chief
Financial Officer
Sirona
Biochem Corp.
Phone:
604.282.6064
Email:
chopton@sironabiochem.com
---------------------------------------------
Sirona Biochem
cautions you that statements included in this press release that
are not a description of historical facts may be forward-looking
statements. Forward-looking statements are only predictions based
upon current expectations and involve known and unknown risks and
uncertainties. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of release of the relevant information, unless explicitly stated
otherwise. Actual
results, performance or achievement could differ materially from
those expressed in, or implied by, Sirona Biochem’s forward-looking
statements due to the risks and uncertainties inherent in Sirona
Biochem’s business including, without limitation, statements about:
the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval,
producing and marketing its products; unexpected adverse side
effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization;
the scope and validity of patent protection for its products;
competition from other pharmaceutical or biotechnology companies;
and its ability to obtain additional financing to support its
operations. Sirona Biochem does not assume any obligation to update
any forward-looking statements except as required by
law.
Sirona Biochem (PK) (USOTC:SRBCF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Sirona Biochem (PK) (USOTC:SRBCF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024